Stockscreener 앱 받기
128.69
0.18%
0.23
시장 영업 전:
128.69
Biogen Inc 주식(BIIB)의 최신 뉴스
Samsung Bioepis Partners with Harrow to Expand US Ophthalmology Market - Asia Business Outlook
Edgestream Partners L.P. Sells 3,285 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
What drives Biogen Inc. stock priceBreakthrough investment results - Jammu Links News
Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Leo Wealth LLC - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Acquires 736,301 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Global Motor Neuron Disease Treatment Market to Exhibit Substantial Growth at a CAGR of ~6% by 2032 | DelveInsight - GlobeNewswire
Biogen’s Innovative Approach to SMA Treatment: The PIERRE-PK Study - TipRanks
Biogen’s Spinraza Study: Real-World Insights and Market Impact - TipRanks
Biogen’s New Study on MS Drug Vumerity: Key Insights for Investors - TipRanks
Biogen’s Promising Phase 3 Trial: Felzartamab for Kidney Transplant Rejection - TipRanks
Düsseldorf court to hear Tecfidera PI appeal as Biogen fights to stop generics - JUVE Patent
What is William Blair's Estimate for Biogen Q3 Earnings? - MarketBeat
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States - Business Wire
Biogen Inc. (NASDAQ:BIIB) Stock Position Reduced by Massachusetts Financial Services Co. MA - MarketBeat
Wedbush Forecasts Biogen's Q2 Earnings (NASDAQ:BIIB) - MarketBeat
Cwm LLC Grows Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
New York State Common Retirement Fund Acquires 20,130 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Alps Advisors Inc. Purchases Shares of 2,500 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Cerity Partners LLC Increases Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Biogen Executive Makes Significant Stock Sale - TipRanks
Insider Selling: Biogen Inc. (NASDAQ:BIIB) Insider Sells 2,223 Shares of Stock - MarketBeat
Brown Advisory Inc. Trims Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Phase 3 Study on Felzartamab for IgA Nephropathy: Market Implications - TipRanks
Wedbush Forecasts Biogen's Q3 Earnings (NASDAQ:BIIB) - MarketBeat
Orphan Drugs Market Expansion Fueled by Rare Disease Research - openPR.com
William Blair Comments on Biogen's Q2 Earnings (NASDAQ:BIIB) - MarketBeat
Cognition Enhancing Drugs Market CAGR 5.6 % innovations and key - openPR.com
State of Michigan Retirement System Has $5.43 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
FY2025 EPS Estimates for Biogen Reduced by Leerink Partnrs - MarketBeat
Erythromelalgia Treatment Market Growing with Rare Disease - openPR.com
Wedbush Raises Price Target on Biogen to $129 From $121, Keeps Neutral Rating - MarketScreener
Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors - GlobeNewswire Inc.
Biogen’s New Study on Omaveloxolone for Young FA Patients: Market Insights - TipRanks
SMN1 Gene Replacement Market 2025: Increasing SMA Population - openPR.com
Spinocerebellar Ataxias Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc, Biohaven Pharma - Barchart.com
Nisa Investment Advisors LLC Cuts Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Holdings Cut by Greenleaf Trust - MarketBeat
M&T Bank Corp Has $1.68 Million Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
When (BIIB) Moves Investors should Listen - news.stocktradersdaily.com
Banque Pictet & Cie SA Purchases 4,780 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Bank of New York Mellon Corp Decreases Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Gene Therapy Market to Hit US$36.55 Billion by 2032 with 19.4% CAGR | MarketsandMarkets™ - Barchart.com
HSBC Raises Price Target on Biogen to $144 From $121, Maintains Hold Rating - MarketScreener
Biogen Inc.'s (NASDAQ:BIIB) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock? - 富途牛牛
JPMorgan maintains Neutral rating on Biogen stock amid gradual Leqembi ramp - Investing.com Nigeria
Case builds for Biogen, Stoke's Dravet syndrome drug - pharmaphorum
Allspring Global Investments Holdings LLC Has $1.43 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Phase 3 Study on Felzartamab for IgA Nephropathy: A Market Game-Changer? - TipRanks
RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT - Insider Monkey
Biogen (BIIB) Presents Promising Data from Zorevunersen Studies - GuruFocus
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress - Biogen
Revolutionary Dravet Syndrome Treatment: Biogen's Zorevunersen Delivers Cognitive Gains in Phase 3 Trial - Stock Titan
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress - Business Wire
Teacher Retirement System of Texas Trims Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Japan to Cut Price of Alzheimer's Drug Lecanemab - nippon.com
US FDA approves gradual dosing for Lilly Alzheimer's drug - Reuters
Biogen Insiders Sold US$1.8m Of Shares Suggesting Hesitancy - simplywall.st
Biogen Inc. shares rise 3.07% intraday after UCB expands BIMZELX® 'Get Yourself Back' campaign. - AInvest
Biogen's top products from 2022 to 2024, based on revenue - Statista
Biogen sees negative Q2 impact from IPR&D, milestone expenses - Seeking Alpha
0.27%
0.96%
자본화:
|
볼륨(24시간):